ALK Allergy Drug Nothing to Sneeze At, European Regulators Say
Danish drugmaker ALK has won European approval for its tree pollen allergy treatment Itulazak.
Itulazak (tree SLIT-tablet) is aimed at adults with moderate-to-severe allergic rhinitis and/or conjunctivitis caused by tree pollens.
The approval comes after ALK handed up data from a Phase 3 trial that found the treatment reduced the total combined allergy score of patients by 40 percent compared to patients in the placebo group.
ALK hopes to launch Itulazak in Germany and Scandinavia by the end of the year.